Capecitabine(Xeloda)

• Catalog No.: S1156
• CAS Number: 154361-50-9
• M. F.: C15H22FN3O6
• M. W.: 359.3500832
• Storage: -20°C

SYNONYMS

• IUPAC name: pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate
• IUPAC Traditional name: capecitabine
• Synonyms: Xeloda

DATABASE IDS

• CAS Number: 154361-50-9

PROPERTIES

• Target: Antimetabolites
• Salt Data: Free Base
• Solubility: DMSO
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Glioma,Oesophageal cancer, Colorectal cancer

Biological Activity

• Description: Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.
• In Vitro: Both LS174T WT and LS174T-c2 cells show significantly greater sensitivity to Capecitabine when cultivated in the same plates as HepG2 hepatoma with IC50 values of 890 and 630 μM in LS174T WT alone and cultivated with HepG2, respectively. In addition, for the LS174T-C2 subline, the IC50 falls from 330 ± 4 down to 89 ± 6 μm when cultivated in the same plates as hepatoma cells. Furthermore, Capecitabine induces apoptosis in a Fas-dependent manner, and shows a 7-fold higher cytotoxicity and markedly stronger apoptotic potential in thymidine phosphorylase (TP)-transfected LS174T-c2 cells. ^[1]
• In Vivo: In the human cancer xenograft models studied, Capecitabine is more effective in a wider dose range and has a broader spectrum of antitumor activity than 5-FU, UFT or its intermediate metabolite 5'-DFUR, which can be correlated with tumor dThdPase levels. ^[2] Capecitabine inhibits tumor growth and metastatic recurrence after resection of human hepatocellular carcinoma (HCC) in highly metastatic nude mice model which is attributed to the high expression of platelet-derived endothelial cell growth factor in tumors. ^[3]
• Clinical Trials: Capecitabine is currently under investigation in Phase II clinical trials in patients with Breast Cancer Metastasis.
• Features: Capecitabine is a tumor-selective fluoropyrimidine carbamate.

Protocol

• Protocol: Cell Assay ^[1]
• Cell Lines: HepG2, LS174T WT and LS174T-c2 cells
• Concentrations: ~1 mM
• Incubation Time: 72 hours
• Methods: HepG2 and either LS174T WT or LS174T-c2 cells are seeded, respectively, in the top and bottom chambers of 8-well strip membranes in 96-well plates. The exponentially growing cells are exposed to increasing concentrations of capecitabine. The medium is supplemented with 750 ng/mL ZB4 MoAB or 100 ng/mL BR17 MoAB when the latter are used in the experiments. After 72 hours of continuous exposure, LS174T viability is assessed using the classic colorimetric MTT test.
• Protocol: Animal Study ^[2]
• Animal Models: BALB/c nu/nu mice are inoculated s.c. with small pieces of CXF280 xenograft tissues
• Formulation: Capecitabine is dissolved in water.
• Doses: ≤1.5 mM/kg/day
• Administration: Administered via p.o.

References

• References: [1] Ciccolini J, et al. Mol Cancer Ther. 2002, 1(11), 923-927.
• References: [2] Ishikawa T, et al. Biochem Pharmacol. 1998, 55(7), 1091-1097.
• References: [3] Zhou J, et al. Clin Cancer Res. 2003, 9(16), 6030-6037.

REFERENCES

• Ciccolini J, et al. Mol Cancer Ther. 2002, 1(11), 923-927.
• Ishikawa T, et al. Biochem Pharmacol. 1998, 55(7), 1091-1097.
• Zhou J, et al. Clin Cancer Res. 2003, 9(16), 6030-6037.